About: EFPIA

Health 25-10-2018

Does fast-track drugs approval in EU run too fast?

More than two years after its launch, the EU's fast-track approval process for marketing new drugs, called PRIME, is broadly welcomed by patients and industry, walking the fine line between patients' safety and expediency, and between the need to foster innovation and remaining abuse-proof.
Economy & Jobs 19-09-2018

Drug industry reacts to Oxfam’s allegations of tax-dodging

Four of the world’s biggest pharma companies appear to hide their profits in tax havens, according to a report published by Oxfam on Tuesday (18 September). Businesses said they are in the clear.
Health 03-07-2018

EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation

The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.  
Health 08-05-2018

Time to end fragmentation of EU healthcare, experts say

Experts are asking for a more collaborative approach in EU healthcare and greater involvement of the European Commission in order to face rising challenges and put patients at the core of decision-making.
Health 07-05-2018

Pharma boss: Incentives based on outcomes will optimise EU healthcare

An outcomes-based approach for incentives in the pharmaceutical sector would help optimise the entire healthcare systems, Nathalie Moll told EURACTIV.com in an interview.
Health 07-12-2017

Celgene boss: Chronic diseases will bankrupt Europe if incentives are dropped

Alzheimers, diabetes, cancer and other non-communicable diseases will bankrupt Europe if we don’t keep the incentive frameworks alive and well, Mark Alles told EURACTIV.com in an interview.
Health 13-10-2017

New Commission study fuels generic drugs industry ‘manufacturing dispute’

The European Commission launched on Thursday (12 October) a public consultation on supplementary protection certificates for pharmaceutical products and the so-called Bolar patent research exemption.
Health 10-10-2017

Pharma boss: Targeting drugs won’t make healthcare systems more sustainable

“Salami-slicing” the cost of medicines, which represent almost one-fifth of health system budgets and are subject to rigorous value assessments, won’t make healthcare systems more sustainable in the future, Nathalie Moll told EURACTIV.com in an interview.
Health 10-07-2017

Pharma firms and consumer groups united over EMA relocation

EU leaders should make a patient-oriented decision on the relocation of the European Medicines Agency (EMA) from London and ensure “minimal disruption”, according to the pharmaceutical industry and consumer groups.
Health 02-09-2015

Big pharma complains about French law pushing cheap eye drug

Europe's pharmaceuticals industry said on Tuesday (1 September) it had filed a complaint with the European Commission against a French law promoting the use of Roche's cancer drug Avastin as an alternative to more expensive eye treatments.
Health 14-03-2011

Pharma chief: Europe must not fall behind US, emerging countries

Brian Ager, Director-General of the European Federation of Pharmaceutical Industries and Associations (EFPIA), is leaving his position after 16 years at the head of the trade association. In an interview with EURACTIV, he reflects on his tenure and discusses some of the new legislation and controversies affecting the pharmaceutical industry.